Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 8Sarcoma 4Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Thoracic 1Other solid neoplasm 1Gynecologic 1Endocrine 1Breast 1

Conditions

Urinary Bladder Neoplasms 117Carcinoma, Transitional Cell 39Testicular Neoplasms 23Urethral Neoplasms 18Testicular Germ Cell Tumor 14Ovarian Neoplasms 13Teratoma 12Prostatic Neoplasms 11Endodermal Sinus Tumor 11Seminoma 10Neoplasms 10Carcinoma, Embryonal 9Ureteral Neoplasms 8Melanoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Renal Cell 7Stomach Neoplasms 6Penile Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 6Breast Neoplasms 6Urologic Neoplasms 5Sarcoma 5Pancreatic Neoplasms 5Urothelial Cancer 4Lung Neoplasms 4Central Nervous System Neoplasms 4Wilms Tumor 3Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3

Interventions

Magnetic Resonance Spectroscopy 10X-Rays 7Specimen Handling 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 6ulixertinib 3palbociclib 3larotrectinib 3erdafitinib 3Temozolomide 3tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ensartinib 2Vemurafenib 2Thalidomide 2Paclitaxel 2Nivolumab 2LY3023414 2Gemcitabine 2Erlotinib Hydrochloride 2Cisplatin 2Carboplatin 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioma × Cisplatin × Genitourinary × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT04851834 2022-12-20

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Xennials Therapeutics Australia Pty Ltd

Phase 1/2 Terminated
12 enrolled
CNSGenitourinaryGynecologic

Urinary Bladder Neoplasms, Glioma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡